adagrasib
mirati
['lcsm,(-blcsm)', 'sclc', 'nsclc', 'adagrasib']
 impressive adagrasib data for metastatic nsclc pts w/krasg12c mutation. 42.9% pts w/objective response(orr). preclinical studies show adagrasib penetrates cns. pts w/stable cns mets intracranial orr 33.3%. #lcsm #asco22 #justpublished 
??Oncologist|??Cancer Researcher|President Ky @ASCO|MedSchool Professor @UofL|Faculty @ASCO @NCCN @OncoAlert|Advisor @MedScape @Onclive @Doximity|#MedTwitter